Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 Feb 11, 2025
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Feb 3, 2025
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Jan 10, 2025
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 Oct 24, 2024
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® Sep 6, 2024
